Gedea Biotech has announces that the treatment of the first patients with its lead product, pHyph, a vaginal tablet for topical treatment, has begun.

The open-labelled study is designed to confirm the safety and efficacy of pHyph in treating adult women with confirmed Vulvo Vaginal Candidiasis (VVC) and in restoring a beneficial vaginal microbiome to prevent recurrence of the infection. The study is being conducted at four Swedish gynecological clinics.

“In previous studies, pHyph has shown a good effect in treating BV in line with antibiotics on the market, but with superior safety profile and without causing the secondary candida infections and the high recurrence seen when treating BV with antibiotics. pHyph has furthermore in previous clinical studies been shown to restore the beneficial vaginal microbiome, important also for treating and preventing vaginal candida infections. The aim of this study is to confirm the safety and efficacy of pHyph in treating VVC. A product with dual effect in treating bacterial vaginosis and vaginal candidiasis would be an ideal treatment for the large group of women who are uncertain of which type of infection that causes their symptoms,” says Annette Säfholm, CEO of Gedea Biotech.

Photo of Annette Säfholm